Cognitive training as a bona fide therapeutic

The New Scientist reports that Brain Plasticity, Inc. a developer of cognitive training games, has entered into discussions with the FDA to market one of its brain training software packages as a bona fide therapeutic. The issue is of interest on many accounts, and the New Scientist article covers many of the obvious ones that were discussed at the Entertainment Software and Cognitive Neurotherapeutics Society meeting held last week in San Francisco.  Noteworthy among them are the hope that FDA approval will bring validity to a field that has both serious practitioners and charlatans others who cut corners, as well as the concern that FDA approval might slow down progress, as the approval process is likely to be glacial compared to the pace of change in software development.

But if we unpack this a bit, we find that there are deeper levels of significance, and at least one of these are is worthy of further discussion. Continue reading